Health TidingsOutlook Therapeutics Charts Regulatory Path Forward for LYTENAVA After FDA ... Outlook Therapeutics Charts Regulatory Path Forward for LYTENAVA After FDA ... Read Post »
ResearchGLP-1 Weight Loss Is Driving New Demand for Facial Aesthetic Treatments, Al... GLP-1 Weight Loss Is Driving New Demand for Facial Aesthetic Treatments, Al... Read Post »
Clinical TrailsFibroBiologics Nears Trial Initiation for CYWC628 in Diabetic Foot Ulcers FibroBiologics Nears Trial Initiation for CYWC628 in Diabetic Foot Ulcers Read Post »
New Drug ApprovalJ&J’s TECVAYLI–DARZALEX FASPRO Combo Wins FDA Approval After MajesT... J&J’s TECVAYLI–DARZALEX FASPRO Combo Wins FDA Approval After MajesT... Read Post »
Health TidingsCanada Taps CSL Seqirus for Cell-Based Pandemic Flu Vaccines in New Prepare... Canada Taps CSL Seqirus for Cell-Based Pandemic Flu Vaccines in New Prepare... Read Post »
Health TidingsOral Epinephrine on Track: Aquestive Maps Path Forward for Anaphylm Oral Epinephrine on Track: Aquestive Maps Path Forward for Anaphylm Read Post »
Health Tidings Policy & AcquisitionsSanofi Licenses Rovadicitinib from Sino Biopharm in $1.53B Global Deal Sanofi Licenses Rovadicitinib from Sino Biopharm in $1.53B Global Deal Read Post »
Clinical TrailsBiogen and Stoke Therapeutics Report Up to 91% Seizure Reduction with Zorev... Biogen and Stoke Therapeutics Report Up to 91% Seizure Reduction with Zorev... Read Post »
Health TidingsBridging Obesity Care Gaps: Lilly’s New Employer Platform Bridging Obesity Care Gaps: Lilly’s New Employer Platform Read Post »
New Drug ApprovalGlenmark Secures FDA Approval and CGT Exclusivity for Generic Fluticasone Glenmark Secures FDA Approval and CGT Exclusivity for Generic Fluticasone Read Post »
Health Tidings Policy & AcquisitionsDuvakitug Gets $400M Boost: Teva’s IBD Pivot with Blackstone Duvakitug Gets $400M Boost: Teva’s IBD Pivot with Blackstone Read Post »
Clinical TrailsAmpreloxetine Misses Primary Endpoint in MSA-nOH CYPRESS Trial, Triggers Sa... Ampreloxetine Misses Primary Endpoint in MSA-nOH CYPRESS Trial, Triggers Sa... Read Post »
Health Tidings Policy & AcquisitionsGSK Finalizes $2.2B RAPT Buyout: Ozureprubart Eyes Quarterly Dosing for Foo... GSK Finalizes $2.2B RAPT Buyout: Ozureprubart Eyes Quarterly Dosing for Foo... Read Post »
Policy & AcquisitionsUCB Bets Big on ATG-201: $1.1B License Deal with Antengene for B-Cell Autoi... UCB Bets Big on ATG-201: $1.1B License Deal with Antengene for B-Cell Autoi... Read Post »
Health TidingsModerna Settles Global Patent Litigation with Arbutus and Genevant for $950... Moderna Settles Global Patent Litigation with Arbutus and Genevant for $950... Read Post »
Health TidingsFDA Cracks Down on Illegal Marketing of Compounded GLP-1 Drugs, Issues Warn... FDA Cracks Down on Illegal Marketing of Compounded GLP-1 Drugs, Issues Warn... Read Post »
Health TidingsJapan Grants Orphan Drug Status to Sanofi’s Rilzabrutinib for Rare IgG4-R... Japan Grants Orphan Drug Status to Sanofi’s Rilzabrutinib for Rare IgG4-R... Read Post »
New Drug ApprovalAgios’ PYRUKYND Gains UAE Approval as First Therapy for Thalassemia P... Agios’ PYRUKYND Gains UAE Approval as First Therapy for Thalassemia P... Read Post »
Health TidingsFDA Grants Priority Review to Takeda’s Rusfertide for Polycythemia Vera FDA Grants Priority Review to Takeda’s Rusfertide for Polycythemia Vera Read Post »
Drugs Safety AlertKyowa Kirin Discontinues All Rocatinlimab Trials Over Emerging Malignancy R... Kyowa Kirin Discontinues All Rocatinlimab Trials Over Emerging Malignancy R... Read Post »
Clinical TrailsIntellia Unveils Striking Long-Term Data on CRISPR Therapy Lonvo-z for Here... Intellia Unveils Striking Long-Term Data on CRISPR Therapy Lonvo-z for Here... Read Post »
Health TidingsJohnson & Johnson Advances Nipocalimab in Lupus with Latest FDA Fast Tr... Johnson & Johnson Advances Nipocalimab in Lupus with Latest FDA Fast Tr... Read Post »
Health TidingsOno Leverages Congruence Revenir™ for Neurology, Immunology Breakthroughs Ono Leverages Congruence Revenir™ for Neurology, Immunology Breakthroughs Read Post »
Health TidingsAtara and Pierre Fabre Seek FDA Type A Meeting to Advance Tab-Cel After CRL Atara and Pierre Fabre Seek FDA Type A Meeting to Advance Tab-Cel After CRL Read Post »
Health TidingsFDA Grants Rare Public Hearing on Vanda’s HETLIOZ® Jet Lag Approval ... FDA Grants Rare Public Hearing on Vanda’s HETLIOZ® Jet Lag Approval ... Read Post »
Policy & AcquisitionsCullgen Joins Gyre in $300M Pact, Boosting Protein Degraders Cullgen Joins Gyre in $300M Pact, Boosting Protein Degraders Read Post »
Clinical TrailsMerck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Merck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Read Post »
Health TidingsPhase 3 Setback for Aardvark’s ARD-101 as HERO Enrollment Freezes Phase 3 Setback for Aardvark’s ARD-101 as HERO Enrollment Freezes Read Post »
Clinical Trails55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... 55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... Read Post »
New Drug ApprovalHERNEXEOS® Gains FDA Nod as First-Line Option for HER2-Mutant NSCLC HERNEXEOS® Gains FDA Nod as First-Line Option for HER2-Mutant NSCLC Read Post »
Health TidingsIntellia Gains Complete FDA Greenlight for Nex-z ATTR Trials Post-Hold Reso... Intellia Gains Complete FDA Greenlight for Nex-z ATTR Trials Post-Hold Reso... Read Post »
Health TidingsJohnson & Johnson Unveils Promising Phase 1b Data for Pasritamig Plus D... Johnson & Johnson Unveils Promising Phase 1b Data for Pasritamig Plus D... Read Post »
New Drug ApprovalFDA Approves Once-Weekly YUVIWEL® for Pediatric Achondroplasia FDA Approves Once-Weekly YUVIWEL® for Pediatric Achondroplasia Read Post »
Clinical TrailsAbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... AbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... Read Post »
Health TidingsHuntington’s Hope Dims? FDA Urges Sham-Controlled Trial for uniQure AMT-1... Huntington’s Hope Dims? FDA Urges Sham-Controlled Trial for uniQure AMT-1... Read Post »
Health TidingsRoche Fenebrutinib Phase III Success: 51% Fewer MS Relapses Roche Fenebrutinib Phase III Success: 51% Fewer MS Relapses Read Post »
Clinical TrailsMerck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Merck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Read Post »
Health TidingsFDA Accepts BLA for Imsidolimab: A Precision Therapy Poised to Transform Ge... FDA Accepts BLA for Imsidolimab: A Precision Therapy Poised to Transform Ge... Read Post »
Clinical TrailsSystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... SystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... Read Post »
Clinical TrailsOrganon Highlights VTAMA Family Sleep Benefits in ADORING Trials Organon Highlights VTAMA Family Sleep Benefits in ADORING Trials Read Post »
Health TidingsOno Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan Ono Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan Read Post »
Lifestyle WellnessMelatonin for Better Sleep: Mechanisms and Evidence from Clinical Trials Melatonin for Better Sleep: Mechanisms and Evidence from Clinical Trials Read Post »
Health TidingsFDA Grants Priority Review to Ionis’ Olezarsen for Severe Hypertrigly... FDA Grants Priority Review to Ionis’ Olezarsen for Severe Hypertrigly... Read Post »
Health TidingsEMA CHMP Backs Moderna’s mCOMBRIAX®: Pioneering Flu-COVID Combo Vacc... EMA CHMP Backs Moderna’s mCOMBRIAX®: Pioneering Flu-COVID Combo Vacc... Read Post »
Clinical TrailsLilly’s Olumiant Shows Strong Hair Regrowth in Adolescents with Sever... Lilly’s Olumiant Shows Strong Hair Regrowth in Adolescents with Sever... Read Post »
Health Tidings Policy & AcquisitionsNovartis Finalizes $12B Avidity Buyout for AOC Muscle Tech Novartis Finalizes $12B Avidity Buyout for AOC Muscle Tech Read Post »
New Drug ApprovalFDA Approves BioMarin PALYNZIQ for Adolescents with PKU FDA Approves BioMarin PALYNZIQ for Adolescents with PKU Read Post »
Clinical TrailsBayer’s PEACE‑3 Phase III Trial Shows Enzalutamide Plus Radium‑223 Im... Bayer’s PEACE‑3 Phase III Trial Shows Enzalutamide Plus Radium‑223 Im... Read Post »
Health Tidings Policy & AcquisitionsEarendil Labs Secures $885M WuXiTecan-2 Rights from WuXi XDC Earendil Labs Secures $885M WuXiTecan-2 Rights from WuXi XDC Read Post »
Health TidingsCHMP Backs Single-Dose Acoziborole to End Gambiense Sleeping Sickness Era CHMP Backs Single-Dose Acoziborole to End Gambiense Sleeping Sickness Era Read Post »
